EURONEXT-AMS$LKFT
Galapagos · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Lakefront Biotherapeutics (LKFT) reported Q1 2026 net revenues of €6.5M with net profit of €14.5M.
Galapagos/Lakefront reported €6.5 million of net revenues for the quarter ended March 31, 2026, down from €75.0 million as prior-year Gilead platform revenue rolled off. Net profit was €14.5 million versus a €153.4 million loss a year ago, helped by €77.7 million of net financial income and fair-value gains. Cash and financial investments totaled roughly €3.0 billion; the Gilead/Ouro transaction is expected to close in Q2 2026.
- Lakefront Biotherapeutics (LKFT) reported Q1 2026 net revenues of €6.
- Quarter ended 2026-03-31; filing date 2026-05-06.
- Revenue of about $6.5M in the quarter.
- Management expects year-end 2026 cash near €2B after Ouro deal and guides €60–75M of 2026 Ouro-related spend; rebranding…
Headline financials
Revenue & EPS history
Galapagos · Revenue · Quarterly
€6.5M
Forward guidance
Management expects year-end 2026 cash near €2B after Ouro deal and guides €60–75M of 2026 Ouro-related spend; rebranding to Lakefront effective May 2026.
Tailwinds
- Net profit on financial income and FX marks.
- Robust cash supports BD and repurchases up to €150M.
- Gilead collaboration on gamgertamig advances.
Headwinds
- Core revenue down without platform recognition.
- Large upfront cash use on Ouro closing.
- Biotech pipeline execution risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
-0.1%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-2.8%
Avg return
30 days after
47%
24 / 51 earnings
Positive
+11.2%
Q3 2023
Best reaction
-7.5%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.3% | +13.2% | +0.4% | |
| Q3 2025 | +0.8% | -1.5% | +1.3% | |
| Q1 2025 | +3.9% | +7.1% | +14.6% | |
| Q3 2024 | -7.4% | -6.4% | -3.2% | |
| Q1 2024 | +0.1% | -1.4% | -5.5% | |
| Q3 2023 | +11.2% | +14.2% | +13.4% | |
| Q2 2023 | +1.4% | -6.7% | -8.9% | |
| Q1 2023 | +6.6% | +4.0% | +3.0% | |
| Q4 2022 | -4.8% | -5.1% | -5.3% | |
| Q3 2022 | -6.9% | -10.4% | -11.9% | |
| Q2 2022 | +3.8% | +1.1% | -5.8% | |
| Q1 2022 | -3.1% | -6.2% | -7.5% | |
| Q4 2021 | +2.2% | +3.0% | -3.4% | |
| Q3 2021 | -3.6% | +0.2% | -16.5% | |
| Q2 2021 | -1.0% | -2.6% | -0.8% | |
| Q1 2021 | -2.4% | -4.3% | -4.2% | |
| Q4 2020 | +2.5% | +1.5% | -2.3% | |
| Q3 2020 | -4.9% | -2.6% | -3.1% | |
| Q2 2020 | -0.6% | +3.7% | -17.8% | |
| Q1 2020 | -1.6% | +2.3% | -9.7% | |
| Q4 2019 | +2.8% | -10.7% | -44.7% | |
| Q3 2019 | +7.0% | +13.0% | +20.4% | |
| Q2 2019 | +1.0% | -0.9% | -8.7% | |
| Q1 2019 | -0.1% | +2.5% | +6.3% | |
| Q4 2018 | -2.8% | -2.8% | -1.6% | |
| Q3 2018 | -7.5% | -5.0% | -4.3% | |
| Q2 2018 | -6.0% | -6.8% | -0.9% | |
| Q1 2018 | -2.0% | -3.9% | +9.2% | |
| Q4 2017 | -3.6% | -6.5% | -13.8% | |
| Q3 2017 | -0.8% | -0.5% | -5.9% | |
| Q2 2017 | -2.8% | -6.7% | +8.1% | |
| Q1 2017 | +0.8% | +2.9% | -3.9% | |
| Q4 2016 | -0.4% | +1.3% | +18.2% | |
| Q3 2016 | -3.3% | -6.0% | -4.7% | |
| Q2 2016 | +1.3% | +0.8% | +1.8% | |
| Q1 2016 | -0.4% | — | — | |
| Q4 2015 | -2.6% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | +2.3% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q4 2014 | -1.5% | — | — | |
| Q3 2014 | -1.6% | — | — | |
| Q2 2014 | +5.5% | — | — | |
| Q1 2014 | +0.6% | — | — | |
| Q4 2013 | +0.9% | — | — | |
| Q3 2013 | -1.6% | — | — | |
| Q2 2013 | +2.5% | — | — | |
| Q1 2013 | +1.0% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | +5.9% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q4 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q2 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro